Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Clinical Oncology

• Publication date

  2006-10-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2005.03.4496PMID 17050865
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• New science-based endpoints to accelerate oncology drug development.

  2005cited by this paper
• Clinical trial designs for predictive marker validation in cancer treatment trials.

  2005cited by this paper
• Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.

  2005cited by this paper
• Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice.

  2004cited by this paper
• Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development

  2004cited by this paper
• Risk factors of pneumothorax and bleeding: multivariate analysis of 660 CT-guided coaxial cutting needle lung biopsies.

  2004cited by this paper
• Disclosure of Genetic Information Obtained Through Research

  2004cited by this paper
• Tissue collection for correlative studies in childhood cancer clinical trials: ethical considerations and special imperatives.

  2004cited by this paper
• American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.

  2003cited by this paper
• A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients.

  2003cited by this paper
• Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

  2002cited by this paper
• Clinical trial design for target-based therapy.

  2002cited by this paper
• The validity of the Hospital Anxiety and Depression Scale. An updated literature review.

  2002cited by this paper
• Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.

  2002cited by this paper
• Clinical trial designs for targeted agents.

  2002cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation.

  2001cited by this paper
• The n e w e n g l a n d j o u r n a l of m e d i c i n e

  2001cited by this paper
• Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework

  2001cited by this paper
• Phase I clinical trial design in cancer drug development.

  2000cited by this paper
• O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair.

  1999cited by this paper
• Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.

  1998cited by this paper
• Perceptions of cancer patients and their physicians involved in phase I trials.

  1995cited by this paper
• Ethical issues in phase I oncology research: a comparison of investigators and institutional review board chairpersons.

  1992cited by this paper
• The Hospital Anxiety and Depression Scale

  1983cited by this paper

• Parent and Participant Perspectives on Research Biopsies in Pediatric Solid Malignancies

  2025cites this paper
• Amplifying the Patient's Voice in Oncology Early-Phase Clinical Trials: Solutions to Burdens and Barriers.

  2024cites this paper
• An Expanded Role for IRBs in the Oversight of Research Biopsies.

  2022cites this paper
• Therapeutic Misconception about Research Procedures: Does a Simple Information Chart Improve Understanding?

  2022cites this paper
• Current studies and future directions for medulloblastoma: A review from the pacific pediatric neuro-oncology consortium (PNOC) disease working group

  2022cites this paper
• Consistent expression of PD-L1 in tumor microenvironment with peripheral PD-1/PD-L1 in circulating T lymphocytes of operable breast cancer: a diagnostic test

  2022cites this paper
• Analyses of the rationale and implementation of research biopsies in oncology clinical trials at a tertiary cancer center.

  2021influential citation
• Translation and validation of the greek version of a questionnaire measuring patient views on participation in clinical trials

  2021cites this paper
• Systematic review and meta-analysis of breast cancer brain metastasis and primary tumor receptor expression discordance

  2021cites this paper
• Perceptions of patients with early stage breast cancer toward research biopsies

  2020cites this paper
• Development of Pharmacodynamic Biomarkers for Phase I Trials

  2020cites this paper
• Phase I Oncology Drug Development

  2020influential citation
• Ethical Framework for Including Research Biopsies in Oncology Clinical Trials: American Society of Clinical Oncology Research Statement.

  2019cites this paper
• Clinical Implications of Evolutionary Modeling of Cancer Progression

  2019cites this paper
• Patient advocate involvement in the design and conduct of breast cancer clinical trials requiring the collection of multiple biopsies

  2018cites this paper
• Attitudes of patients with metastatic cancer towards research biopsies

  2018cites this paper
• Attitudes of Patients With Gastrointestinal Cancers Toward Research Biopsies

  2017cites this paper
• Genomic Adequacy from Solid Tumor Core Needle Biopsies of ex Vivo Tissue and in Vivo Lung Masses: Prospective Study.

  2017cites this paper
• Racing for Consent: A Feminist Relational Analysis of Informed Consent for Nondiagnostic Breast Cancer Research Biopsies

  2017cites this paper
• Attitudes of patients and physicians on repeat biopsies for lung cancer

  2017cites this paper
• The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017)

  2017cites this paper
• Presurgical window of opportunity trial design as a platform for testing anticancer drugs: Pros, cons and a focus on breast cancer.

  2016cites this paper
• Patients’ willingness to participate in clinical trials and their views on aspects of cancer research: results of a prospective patient survey

  2016influential citation
• Patients with Advanced Non–Small Cell Lung Cancer: Are Research Biopsies a Barrier to Participation in Clinical Trials?

  2016cites this paper
• Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials.

  2016cites this paper
• Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses

  2016cites this paper
• Failures in Phase III: Causes and Consequences

  2015cites this paper
• Ethics of Cancer Gene Transfer Clinical Research.

  2015cites this paper
• Variation in the Attitudes of Medical Oncologists Toward Research Biopsies in Patients With Metastatic Breast Cancer.

  2015cites this paper
• Safety and diagnostic accuracy of tumor biopsies in children with cancer

  2015cites this paper
• Patients' Understanding of How Genotype Variation Affects Benefits of Tamoxifen Therapy for Breast Cancer

  2014cites this paper
• Patients' Perceptions of Research Biopsies in Phase I Oncology Trials

  2014cites this paper
• Consent for nondiagnostic research biopsies: a pilot study of participant recall and therapeutic orientation.

  2014cites this paper
• Pharmacodynamic Biomarkers: Falling Short of the Mark?

  2014cites this paper
• Phase 0 Trials in Oncology

  2014cites this paper
• Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail

  2014cites this paper
• Genomic testing in cancer: Patient knowledge, attitudes, and expectations

  2014cites this paper
• A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin

  2014cites this paper
• Attitudes of patients with metastatic breast cancer toward research biopsies.

  2013cites this paper
• Biopsies: next-generation biospecimens for tailoring therapy

  2013cites this paper
• Analysis of consent validity for invasive, nondiagnostic research procedures.

  2013cites this paper
• Factors related to biopsy willingness in patients with advanced cancer in a phase 1 clinic for molecularly targeted therapy

  2013cites this paper
• Prospective clinical experience with research biopsies in breast cancer patients

  2013cites this paper
• Feasibility and safety of sequential research‐related tumor core biopsies in clinical trials

  2013cites this paper
• Reporting practices of pharmacodynamic studies involving invasive research procedures in cancer trials

  2013cites this paper
• Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study.

  2013cites this paper
• Research Biopsies in the Context of Early Phase Oncology Studies: Clinical and Ethical Considerations

  2013cites this paper
• Physician Recruitment of Patients to Non-Therapeutic Oncology Clinical Trials: Ethics Revisited

  2013cites this paper
• Use of research biopsies in clinical trials: are risks and benefits adequately discussed?

  2013cites this paper
• Toward improved understanding of the ethical and clinical issues surrounding mandatory research biopsies.

  2013cites this paper
• Prevalence and impact of correlative science in breast cancer phase II trials

  2013cites this paper
• Chapter 35 – Informed Consent

  2013cites this paper
• Feasibility of Image-Guided Transthoracic Core-Needle Biopsy in the BATTLE Lung Trial

  2013cites this paper
• Usefulness of prestudy assessment of patient willingness to undergo tissue biopsy for correlative studies in a melanoma vaccine trial

  2013cites this paper
• Prospective clinical experience with research biopsies in breast cancer patients.

  2013cites this paper
• Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety.

  2012cites this paper
• Challenges and opportunities in the use of CTCs for companion diagnostic development.

  2012cites this paper
• Indeterminate pulmonary nodules in rectal cancer: A recommendation for follow‐up guidelines

  2012cites this paper
• Ethical Issues in Using Bronchial Biopsies for Asthma Research

  2012influential citation
• Pharmacodynamic end points in early phase oncology trials

  2012cites this paper
• Publication and Reporting Conduct for Pharmacodynamic Analyses of Tumor Tissue in Early-Phase Oncology Trials

  2012cites this paper
• Research biopsies in phase I studies: views and perspectives of participants and investigators.

  2012cites this paper
• Optimising the Development of Antibodies as Treatment for Cancer

  2011cites this paper
• Pharmacodynamic Studies in Early Phase Drug Development

  2011cites this paper
• Making personalized medicine a reality: the challenges of a modern translational research biopsy-driven program in an academic setting: the Segal Cancer Center experience

  2011cites this paper
• Overlooking Evolution: A Systematic Analysis of Cancer Relapse and Therapeutic Resistance Research

  2011cites this paper
• Patient willingness to undergo pharmacodynamic and pharmacokinetic tests in early phase oncology trials

  2011cites this paper
• The Frequency and Significance of Radiologically Detected Indeterminate Pulmonary Nodules in Patients with Colorectal Cancer

  2011cites this paper
• The ethical use of mandatory research biopsies

  2011cites this paper
• Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience.

  2011cites this paper
• Molecular Cancer apeutics cular Medicine in Practice se I Safety , Pharmacokinetic , and Biomarker Study of F 1120 , an Oral Triple Tyrosine Kinase Inhibitor in Ther ients with Advanced Solid Tumors

  2010cites this paper
• I Safety , Pharmacokinetic , and Biomarker Study of F 1120 , an Oral Triple Tyrosine Kinase Inhibitor in Ther ients with Advanced Solid Tumors

  2010cites this paper
• Selecting systemic cancer therapy one patient at a time: is there a role for molecular profiling of individual patients with advanced solid tumors?

  2010cites this paper
• Informed consent in genomics and genetic research.

  2010cites this paper
• Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

  2010cites this paper
• Early oncology clinical trial design in the era of molecular-targeted agents.

  2010cites this paper
• Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology.

  2010cites this paper
• Patient benefits from psychosocial care: screening for distress and models of care.

  2010cites this paper
• Reasons for participation in optional pharmacokinetic studies in children with cancer: A Children's Oncology Group phase 1 consortium study

  2010cites this paper
• Biomarker-Driven Early Clinical Trials in Oncology: A Paradigm Shift in Drug Development

  2009cites this paper
• Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?

  2009cites this paper
• Are we HER-ting for innovation in neoadjuvant breast cancer trial design?

  2009cites this paper
• A New Conceptualization of Occupational Outcome

  2008cites this paper
• Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy.

  2008cites this paper
• Nomograms to predict serious adverse events in phase II clinical trials of molecularly targeted agents.

  2008cites this paper
• The clinical significance of radiologically detected silent pulmonary nodules in early breast cancer.

  2008cites this paper
• Phase 0 Clinical Trials: Conceptions and Misconceptions

  2008cites this paper
• Biomarkers for DNA DSB inhibitors and radiotherapy clinical trials

  2008cites this paper
• Bench to Bedside: Mapping the Moral Terrain of Clinical Research

  2008cites this paper
• Clinical biomarkers of angiogenesis inhibition

  2008cites this paper
• Mapping the Moral Terrain of Clinical Research

  2008cites this paper
• Performing nondiagnostic research biopsies in irradiated tissue: a review of scientific, clinical, and ethical considerations.

  2008cites this paper
• Performance of biopsies in clinical research.

  2007cites this paper
• Chemotherapy in the Management of Malignant Tumors of Salivary Gland Origin

  2007cites this paper
• Méthodologie des essais de phase I en cancérologie

  2007cites this paper
• [Phase I cancer trials methodology].

  2007cites this paper
• Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer

  2007cites this paper
• Malignancies of the head and neck: the role for molecular targeted agents

  2007cites this paper
• Ethics at Phase 0: Clarifying the Issues

  2007cites this paper
• Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer

  2006cites this paper